TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38233280

Group type: EXPERIMENTAL
Intervention: Adequate sleep (maintenance of habitual bed/wake times)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Insufficient sleep (reduction in sleep of 1.5 hours relative to adequate sleep)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adequate sleep
Number of subjects: 65

Group type: COMPARATOR
Intervention: Insufficient sleep
Number of subjects: 65
Study: 38233512

Group type: EXPERIMENTAL
Intervention: Cumulative social adversity
Number of subjects: 537
Study: 38233570

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study: 38233575

Group type: EXPERIMENTAL
Intervention: i.v. 24 mg dexamethasone
Number of subjects: 31

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 31
Study: 38233586

Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T cell therapy (axicabtagene ciloleucel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard of care (salvage chemotherapy followed by hematopoietic transplantation)
Number of subjects: 0
Study: 38233592

Group type: EXPERIMENTAL
Intervention: 12 year intensive lifestyle intervention
Number of subjects: 4402

Group type: COMPARATOR
Intervention: Diabetes support and education (control)
Number of subjects: 4402
Study: 38233608

Group type: EXPERIMENTAL
Intervention: DROP-IN + LaproFlex combination
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rigid laparoscopic probe
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluorescence guidance
Number of subjects: 10
Study: 38233784

Group type: EXPERIMENTAL
Intervention: Ballet-based dance programme (12 one-weekly sessions)
Number of subjects: 160
Study: 38233810

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 3 weeks for up to 6 cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study: 38233816

Group type: EXPERIMENTAL
Intervention: Thymosin α1 (1.6 mg subcutaneous injections for 24 weeks, daily for the first 2 weeks, biweekly for the next 22 weeks)
Number of subjects: 20
Study: 38233878

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) at 0.07 mg/kg/day initially, adjusted by trough levels
Number of subjects: 86

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) at a maximum of 2000 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) and Mycophenolate mofetil (MMF)
Number of subjects: 86
Study: 38233885

Group type: EXPERIMENTAL
Intervention: IVIg (2.0 g/kg every 4 weeks for 16 weeks)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: IVIg (1.0 g/kg in open-label extension)
Number of subjects: 95
Study: 38233887

Group type: EXPERIMENTAL
Intervention: Continuous Rotation Group (CRG) with EdgeEndo x7 rotary system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reciprocation Group (RG) with EdgeOne Fire reciprocating system
Number of subjects: 20
Study: 38233908

Group type: EXPERIMENTAL
Intervention: CleverCap pill bottle linked to the WiseApp (intervention)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 248
Study: 38233983

Group type: EXPERIMENTAL
Intervention: Blind urine sampling method
Number of subjects: 412

Group type: COMPARATOR
Intervention: Randomized-response questionnaire
Number of subjects: 412
Study: 38234020

Group type: EXPERIMENTAL
Intervention: Mebendazole (50 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day) with bevacizumab (10 mg/kg/dose) and irinotecan (150 mg/m2)
Number of subjects: 10
Study: 38234165

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 38234326

Group type: EXPERIMENTAL
Intervention: Venting Wisely care pathway for HRF and ARDS patients
Number of subjects: 18816

Group type: COMPARATOR
Intervention: Preimplementation group
Number of subjects: 18816

Group type: COMPARATOR
Intervention: Postimplementation group
Number of subjects: 18816
Study: 38234368

Group type: EXPERIMENTAL
Intervention: DELTA intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38234709

Group type: EXPERIMENTAL
Intervention: Online recruitment via social media
Number of subjects: 60
Study: 38234736

Group type: EXPERIMENTAL
Intervention: Nthabi conversational agent system for family planning education
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Nthabi conversational agent system for folic acid education
Number of subjects: 172
Study: 38235411

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 160
Study: 38235421

Group type: EXPERIMENTAL
Intervention: RC48 2.0 mg/kg plus toripalimab 3 mg/kg, q2w
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w (HER2-positive population)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w (low HER2 expressing population)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Other solid tumours (including breast cancer and endometrial carcinoma)
Number of subjects: 56
Study: 38235512

Group type: EXPERIMENTAL
Intervention: Sovleplenib (600 mg q.d. for >65 kg or 400 mg q.d. for ≤65 kg)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Sovleplenib (200-800 mg once daily or 200 mg twice daily)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Sovleplenib (at RP2D)
Number of subjects: 134
Study: 38235519

Group type: EXPERIMENTAL
Intervention: Carfilzomib (20 mg/m2 intravenously in cycle 1 on days 1 and 2, then 56 mg/m2 from day 8 onwards), thalidomide (100 mg orally in the evening), and dexamethasone (40 mg weekly, 20 mg for patients ≥75 years) for 18 months.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Carfilzomib, thalidomide, and dexamethasone (KTd) treatment.
Number of subjects: 93
Study: 38235709

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 89
Study: 38235741

Group type: EXPERIMENTAL
Intervention: CAD-EYE-assisted colonoscopy (CAC)
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: CAC
Number of subjects: 1031

Group type: COMPARATOR
Intervention: CC
Number of subjects: 1031
Study: 38235831

Group type: EXPERIMENTAL
Intervention: 3D consultation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard consultation
Number of subjects: 52
Study: 38235907

Group type: EXPERIMENTAL
Intervention: TIPS placement
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional treatment (paracentesis plus albumin 8 g/L of removed ascites)
Number of subjects: 130
Study: 38235985

Group type: EXPERIMENTAL
Intervention: Outpatient (OPT) management
Number of subjects: 97

Group type: COMPARATOR
Intervention: Inpatient management
Number of subjects: 97
Study: 38236020

Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38236166

Group type: EXPERIMENTAL
Intervention: R2 DPI (low-medium internal resistance)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: R5 DPI (high internal resistance)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Physical position (standing, sitting, semi-upright)
Number of subjects: 76
Study: 38236223

Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes (0.4 mg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate nicotine content cigarettes (2.4 mg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High nicotine content cigarettes (15.8 mg/g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38236233

Group type: EXPERIMENTAL
Intervention: Self-affirmation (SA) exercise
Number of subjects: 484

Group type: COMPARATOR
Intervention: Personalized feedback intervention (PFI)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 484
Study: 38236249

Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept (2-4 mg/kg) plus pembrolizumab (2 mg/kg), administered intravenously every 2 weeks
Number of subjects: 10
Study: 38236314

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study: 38236316

Group type: EXPERIMENTAL
Intervention: MAPSE
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: LV-LWFS
Number of subjects: 152

Group type: COMPARATOR
Intervention: LVEF
Number of subjects: 152

Group type: COMPARATOR
Intervention: s´
Number of subjects: 152

Group type: COMPARATOR
Intervention: LVLS
Number of subjects: 152

Group type: COMPARATOR
Intervention: OSFD
Number of subjects: 152

Group type: COMPARATOR
Intervention: 30-day mortality
Number of subjects: 152
Study: 38236365

Group type: EXPERIMENTAL
Intervention: Tracking methods (self-report, GP report, follow-up call)
Number of subjects: 4470

Group type: COMPARATOR
Intervention: Site reports
Number of subjects: 4470

Group type: COMPARATOR
Intervention: Participant reports
Number of subjects: 4470

Group type: EXPERIMENTAL
Intervention: Geofencing
Number of subjects: 4470
Study: 38236409

Group type: EXPERIMENTAL
Intervention: Dexcom G6 real-time continuous glucose monitoring (rtCGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FreeStyle Libre 1 intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 0
Study: 38236431

Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide (0.5 mg and 1.0 mg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Once-daily sitagliptin (100 mg)
Number of subjects: 110
Study: 38236515

Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA [RBL])
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 38236575

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice daily with Durvalumab 1,500 mg on day 1 every 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Historical control of continued platinum-based therapy
Number of subjects: 45
Study: 38236581

Group type: EXPERIMENTAL
Intervention: Abiraterone or Enzalutamide
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HOXB13 CTC detection
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Low HOXB13 CTC detection
Number of subjects: 118
Study: 38236590

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Fulvestrant
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Anastrozole + Fulvestrant (A+F)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Anastrozole + Fulvestrant (A+F) in luminal B tumors
Number of subjects: 1298
Study: 38236602

Group type: EXPERIMENTAL
Intervention: Nurse home visitation
Number of subjects: 742

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 742
Study: 38236603

Group type: EXPERIMENTAL
Intervention: Internal fixation of well-reduced medial malleolus fractures (n=78)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Nonfixation of medial malleolus fractures (n=76)
Number of subjects: 154
Study: 38236634

Group type: EXPERIMENTAL
Intervention: TIPS app (mHealth tool)
Number of subjects: 11
Study: 38236638

Group type: EXPERIMENTAL
Intervention: 7-week self-help program delivered through a mobile app involving 7 weekly 10-minute videos
Number of subjects: 170

Group type: COMPARATOR
Intervention: Treatment-as-usual condition (waitlist control)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 7-week self-help program
Number of subjects: 170
Study: 38236701

Group type: EXPERIMENTAL
Intervention: External cephalic version with a full bladder
Number of subjects: 70

Group type: COMPARATOR
Intervention: External cephalic version with an empty bladder
Number of subjects: 70
Study: 38236702

Group type: EXPERIMENTAL
Intervention: Adjuvant platinum
Number of subjects: 296

Group type: COMPARATOR
Intervention: Adjuvant capecitabine
Number of subjects: 296
Study: 38237075

Group type: EXPERIMENTAL
Intervention: Wilate prophylaxis for 12 months
Number of subjects: 33
Study: 38237077

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R with ixazomib (3 mg established as recommended phase 2 dose), administered for 6 cycles with ixazomib given twice per 21-day cycle; responders continued weekly ixazomib maintenance for up to 1 year.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R with ixazomib
Number of subjects: 36
Study: 38237090

Group type: EXPERIMENTAL
Intervention: Long-COVID patients
Number of subjects: 105

Group type: COMPARATOR
Intervention: Pandemic controls
Number of subjects: 105

Group type: COMPARATOR
Intervention: Prepandemic controls
Number of subjects: 105

Group type: COMPARATOR
Intervention: Long-COVID patients vs pandemic controls
Number of subjects: 105

Group type: COMPARATOR
Intervention: Long-COVID patients vs prepandemic controls
Number of subjects: 105

Group type: COMPARATOR
Intervention: Pandemic controls vs prepandemic controls
Number of subjects: 105
Study: 38237263

Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 15 minutes daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 30 minutes daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 50 minutes daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 40 minutes daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises for 35 minutes daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mirror movement therapy ankle exercises (various doses)
Number of subjects: 15
Study: 38237373

Group type: EXPERIMENTAL
Intervention: Surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every 3 weeks)
Number of subjects: 40
Study: 38237620

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine 5 mg orally twice daily for 14 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo twice daily for 14 days
Number of subjects: 44
Study: 38237621

Group type: EXPERIMENTAL
Intervention: Neoadjuvant FOLFIRINOX
Number of subjects: 140

Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 140
Study: 38237636

Group type: EXPERIMENTAL
Intervention: LVEF < 45%
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: TAPSE < 17 mm
Number of subjects: 292
Study: 38237674

Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP) delivered via video telehealth (VTH) for up to 16 sessions
Number of subjects: 160

Group type: COMPARATOR
Intervention: Stress management training control delivered via video telehealth (VTH)
Number of subjects: 160
Study: 38237675

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg daily for 7 days followed by 5 mg/kg daily for 7 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 200
Study: 38237696

Group type: EXPERIMENTAL
Intervention: Tradipitant 85 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 38237796

Group type: EXPERIMENTAL
Intervention: Multi-Point Pacing (MPP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard single-site pacing (STD)
Number of subjects: 51
Study: 38237898

Group type: EXPERIMENTAL
Intervention: Ongoing dysglycaemia defined by HbA1c at 4 months
Number of subjects: 348

Group type: COMPARATOR
Intervention: HbA1c levels <5.7%
Number of subjects: 348

Group type: COMPARATOR
Intervention: HbA1c levels ≥5.7%
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Patients with diabetes (pre- and newly diagnosed, n=16) excluded
Number of subjects: 348
Study: 38238052

Group type: EXPERIMENTAL
Intervention: Modified intubation protocol (M group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional intubation process (C group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early resumption of oral intake (E group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed resumption of oral intake (D group)
Number of subjects: 200
Study: 38238050

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after interhospital transfer
Number of subjects: 49
Study: 38238057

Group type: EXPERIMENTAL
Intervention: Public health campaigns/antenatal care adaptation related to modifiable risk factors for late stillbirth.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 38238055

Group type: EXPERIMENTAL
Intervention: Intraperitoneal irinotecan (75 mg) with concomitant mFOLFOX4 and bevacizumab
Number of subjects: 85
Study: 38238058

Group type: EXPERIMENTAL
Intervention: SmartMom messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Messages addressing general topics related to pregnancy without direction for behaviour change
Number of subjects: 0
Study: 38238060

Group type: EXPERIMENTAL
Intervention: HEPA air filtration
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 160
Study: 38238170

Group type: EXPERIMENTAL
Intervention: SIMPlified LaYered consent process
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard informed consent forms (ICFs)
Number of subjects: 0
Study: 38238175

Group type: EXPERIMENTAL
Intervention: Modified Zhiwang decoction (MZWD) combined with methotrexate (MTX)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 150
Study: 38238182

Group type: EXPERIMENTAL
Intervention: Structured Exercise
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Lifestyle
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Combination of Structured Exercise and Lifestyle
Number of subjects: 117

Group type: COMPARATOR
Intervention: Non-responders to initial treatment
Number of subjects: 117
Study: 38238194

Group type: EXPERIMENTAL
Intervention: EUS-guided fine needle injection (EUS-FNI) of large surface area microparticle paclitaxel (LSAM-PTX) at a concentration of 15 mg/mL, with a mean of 4 doses administered (mean dose/cyst: 73 ± 31 mg)
Number of subjects: 5
Study: 38238230

Group type: EXPERIMENTAL
Intervention: Transparent cling film applied over the lower face
Number of subjects: 25

Group type: COMPARATOR
Intervention: No transparent cling film applied (control)
Number of subjects: 25
Study: 38238350

Group type: EXPERIMENTAL
Intervention: Service dog (veterans n=88, partners n=46)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Usual care (control group: n=73, partners n=38)
Number of subjects: 245
Study: 38238599

Group type: EXPERIMENTAL
Intervention: Frequent CC screening
Number of subjects: 753

Group type: COMPARATOR
Intervention: Infrequent CC screening
Number of subjects: 753
Study: 38238620

Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase (TNK) plus Dl-3-n-Butylphthalide (NBP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dl-3-n-Butylphthalide (NBP)
Number of subjects: 100
Study: 38238616

Group type: EXPERIMENTAL
Intervention: Allogeneic CD19-specific CAR-NK cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15)
Number of subjects: 37
Study: 38238666

Group type: EXPERIMENTAL
Intervention: Postoperative nadir platelet count ≤ 99 × 10^9/L
Number of subjects: 113
Study: 38238686

Group type: EXPERIMENTAL
Intervention: Simplified care pathway (intervention group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care pathway (control group)
Number of subjects: 200
Study: 38238707

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) at age 6 to 9 years
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Sport and exercise at age 9 to 11 years
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: MVPA at age 9 to 11 years
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Sleep at age 6 to 9 years
Number of subjects: 1084
Study: 38238747

Group type: EXPERIMENTAL
Intervention: Inadequate care setting based on age and severity at T1 (2015-2016)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Inadequate care setting based on age and severity at T2 (2020-2021)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Global subjective inadequacy at T1 (2015-2016)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Global subjective inadequacy at T2 (2020-2021)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Undermonitoring by medical care providers at T2 (2020-2021)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Gaps in performed vs prescribed paramedical care at T2 (2020-2021)
Number of subjects: 492
Study: 38238759

Group type: EXPERIMENTAL
Intervention: Auditory EEG-based interface using voluntary modulations of attention
Number of subjects: 7

Group type: COMPARATOR
Intervention: Auditory BCI
Number of subjects: 7
Study: 38238788

Group type: EXPERIMENTAL
Intervention: Formula for predicting emphysema extent based on pulmonary function data (percent predicted forced vital capacity, percent predicted forced expiratory volume in 1 second, percent predicted carbon monoxide diffusing capacity).
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Formula for predicting emphysema extent.
Number of subjects: 76
Study: 38238789

Group type: EXPERIMENTAL
Intervention: 0/safety pad definition
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: 0 pads definition
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: ICIQ-SF score
Number of subjects: 718
Study: 38238809

Group type: EXPERIMENTAL
Intervention: Conservative treatment (rehabilitation + optional delayed surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate ACL reconstruction (< 12 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 38238838

Group type: EXPERIMENTAL
Intervention: S-ketamine group (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline group (group 2)
Number of subjects: 100
Study: 38239158

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional behaviour management techniques (Control)
Number of subjects: 60
Study: 38239359

Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg orally once daily) + Camrelizumab (200 mg)
Number of subjects: 26
Study: 38239409

Group type: EXPERIMENTAL
Intervention: Genome-wide association study of serum metabolite levels
Number of subjects: 0